Tag: beigene
June 9, 2021
5 Small Biotech ETFs
Want to invest in small biotech ETFs? INN profiles five examples that life science investors may want to look into. January 15, 2019
BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib
BeiGene (NASDAQ:BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the...
December 20, 2018
5 Top Biotech and Pharma Stocks on the TSX Year-to-Date
Which biotech and pharma stocks on the TSX have performed the best in 2018? Here's a look at the top... November 27, 2018
Zymeworks and BeiGene Announce License and Collaboration Agreement
Zymeworks (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and BeiGene (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company... October 24, 2018
BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib
BeiGene (NASDAQ:BGNE;HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of... October 10, 2018
BeiGene Announces National Reimbursement Inclusion of VIDAZA by the State Medical Insurance Administration in China
BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of... August 31, 2018
